TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7846101

Group type: EXPERIMENTAL
Intervention: Dietary gamma-linolenic acid (GLA) at a dose of 3 g/day for humans and 3 mg/kg/day for rats for 4 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietary gamma-linolenic acid (GLA) at a dose of 3 mg/kg/day for rats for 4 months
Number of subjects: 24
Study: 3398015

Group type: EXPERIMENTAL
Intervention: Teaching skills program for residents; instruction and feedback during first and second postgraduate years
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study: 30642365

Group type: EXPERIMENTAL
Intervention: Intensive motivational tool based on individual risks of pulmonary damage and prevention opportunities, reinforced by individualized text messages over a period of 3 months.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) diagnosis and severity assessment.
Number of subjects: 204
Study: 28258815

Group type: EXPERIMENTAL
Intervention: Xylazine (200 μg kg−1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.875 μg kg−1)
Number of subjects: 6
Study: 25635959

Group type: EXPERIMENTAL
Intervention: Occlusal appliance therapy (OA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Therapist-guided relaxation training (RT)
Number of subjects: 64
Study: 23571234

Group type: EXPERIMENTAL
Intervention: Cirrus HD-OCT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Stratus OCT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mean difference in central foveal zone
Number of subjects: 19
Study: 21914508

Group type: EXPERIMENTAL
Intervention: IVR version of EQ-5D
Number of subjects: 113

Group type: COMPARATOR
Intervention: Paper version of EQ-5D
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: IVR version of EQ VAS
Number of subjects: 113

Group type: COMPARATOR
Intervention: Paper version of EQ VAS
Number of subjects: 113
Study: 19506455

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy with concurrent low-dose daily platinum chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Standard fraction (conventionally fractionated) radiation therapy
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy without concurrent chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Treatment (general)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Lower stage grouping
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CHT)
Number of subjects: 289
Study: 17075912

Group type: EXPERIMENTAL
Intervention: Sertraline plus 10 sessions of twice‐weekly prolonged exposure (PE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 65
Study: 14715071

Group type: EXPERIMENTAL
Intervention: Linear SVM algorithm
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nonlinear SVM algorithm
Number of subjects: 59

Group type: COMPARATOR
Intervention: SVM algorithms (comparison with PCA)
Number of subjects: 59
Study: 11709564

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (250 mg daily) for 2 years
Number of subjects: 380

Group type: COMPARATOR
Intervention: Tamoxifen for 2 more years
Number of subjects: 380
Study: 9146325

Group type: EXPERIMENTAL
Intervention: Sculptor ring
Number of subjects: 221

Group type: COMPARATOR
Intervention: Carpentier‐Edwards ring control
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards ring historical
Number of subjects: 221
Study: 8181847

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 250 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ofloxacin, 200 mg twice daily
Number of subjects: 100
Study: 31471001

Group type: EXPERIMENTAL
Intervention: Website with vaccine information and interactive social media components
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Website with vaccine information only
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 289
Study: 30310936

Group type: EXPERIMENTAL
Intervention: Wallis interspinous device
Number of subjects: 72

Group type: COMPARATOR
Intervention: Primary discectomy
Number of subjects: 72
Study: 27278272

Group type: EXPERIMENTAL
Intervention: Grade 3/4 Chemotherapy-Induced Neutropenia (CIN)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Grade 4 Chemotherapy-Induced Neutropenia (CIN)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Area Over the Curve (AOC) of Absolute Neutrophil Count (ANC)
Number of subjects: 271
Study: 25015695

Group type: EXPERIMENTAL
Intervention: Transradial access (TR)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Transfemoral access (TF)
Number of subjects: 103
Study: 22495908

Group type: EXPERIMENTAL
Intervention: Five-Element Gymnastics (FEG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 66
Study: 20456443

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid eye drops (1%)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 70
Study: 18794494

Group type: EXPERIMENTAL
Intervention: CTLA4Ig infusion
Number of subjects: 16
Study: 15699673

Group type: EXPERIMENTAL
Intervention: Cranial bone grafting for orbital reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exogenous materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iliac bone as autogenous source
Number of subjects: 0
Study: 12842377

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia for 8 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air (control) for 8 hours
Number of subjects: 8
Study: 10330648

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.5%
Number of subjects: 59

Group type: COMPARATOR
Intervention: prednisolone acetate 1%
Number of subjects: 59
Study: 8954018

Group type: EXPERIMENTAL
Intervention: NOMA (5 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NETA (10 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NOMA + FLU (250 mg, twice a day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NETA + FLU (250 mg, twice a day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NOMA and NETA in CAI patients
Number of subjects: 13
Study: 1935866

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus oral Valium
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (CBT only)
Number of subjects: 83
Study: 6216858

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 49
Study: 31321805

Group type: EXPERIMENTAL
Intervention: Consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) within three months after CAR-T therapy for MRD-CR patients.
Number of subjects: 58

Group type: COMPARATOR
Intervention: CAR-T therapy without subsequent allo-HSCT.
Number of subjects: 58
Study: 29065279

Group type: EXPERIMENTAL
Intervention: Gait retraining group (n = 166) received 2 weeks of gait retraining with real-time visual feedback.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (n = 154) received treadmill running exercise without visual feedback.
Number of subjects: 320
Study: 27883172

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate and a high calorie supplement (2108‐2416 kJ/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo testosterone and low calorie supplement (142‐191 kJ/day)
Number of subjects: 53
Study: 24706003

Group type: EXPERIMENTAL
Intervention: COCP pretreatment for 12-16 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-COCP (control group)
Number of subjects: 10
Study: 23017325

Group type: EXPERIMENTAL
Intervention: Combination of aspirin (81 mg) and EPA+DHA (3.4 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (81 mg) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPA+DHA (3.4 g/d) alone
Number of subjects: 0
Study: 20401350

Group type: COMPARATOR
Intervention: GanedenBC(30) - 1 capsule/day for 28 days
Number of subjects: 10
Study: 18029844

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate treatment
Number of subjects: 63
Study: 16265345

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 33
Study: 12181623

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg per os daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg intramuscularly every 10 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10439571

Group type: EXPERIMENTAL
Intervention: Primary care-based chronic pain management program
Number of subjects: 40000
Study: 7776167

Group type: COMPARATOR
Intervention: Disposable polyester foam sponge on a stick with non-foaming dentifrice; used for 1 and 3 minutes respectively.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Commercially-available toothbrush; used for 1 and 3 minutes respectively.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Disposable polyester foam sponge on a stick with non-foaming dentifrice; used 3 times a day for 1 week.
Number of subjects: 67
Study: 2333483

Group type: EXPERIMENTAL
Intervention: Prompting and reinforcement for different activities
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Only prompted
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 111124

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30636771

Group type: EXPERIMENTAL
Intervention: Breast milk (BF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Unsupplemented formula (F0)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Formula supplemented with 65 mg/L bOPN (F65)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Formula supplemented with 130 mg/L bOPN (F130)
Number of subjects: 4
Study: 29945669

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 45
Study: 26740639

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 30 daily sessions of 90 min at 244 kPa
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham treatment - 30 daily sessions of 90 min breathing air at 125 kPa
Number of subjects: 103
Study: 25108448

Group type: EXPERIMENTAL
Intervention: Early ART initiation (CD4 counts above 350 cells/mm(3))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Deferred ART initiation (CD4 counts below 250 cells/mm(3))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall comparison of early vs deferred treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clinical evaluation after study period
Number of subjects: 44
Study: 21983204

Group type: EXPERIMENTAL
Intervention: Commercial for a relatively healthy food item
Number of subjects: 75

Group type: COMPARATOR
Intervention: Commercial for a less healthy food item
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Parental encouragement to choose the healthy item
Number of subjects: 75

Group type: COMPARATOR
Intervention: Choosing whichever item they preferred (no parental encouragement)
Number of subjects: 75
Study: 20400916

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (5 x 10(9) colony‐forming units 3 times per day for 3 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 64
Study: 19902033

Group type: EXPERIMENTAL
Intervention: N. sativa oil 2.5 ml twice daily, atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Number of subjects: 60
Study: 15830199

Group type: EXPERIMENTAL
Intervention: A3 adenosine receptor expression in PEX eyes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal and glaucomatous control eyes
Number of subjects: 0
Study: 12794428

Group type: EXPERIMENTAL
Intervention: Protein C concentrate (200 IU/kg, 400 IU/kg, or 600 IU/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11053728

Group type: EXPERIMENTAL
Intervention: Nonfluoroscopic electromechanical mapping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Echocardiographic data
Number of subjects: 40
Study: 8940984

Group type: EXPERIMENTAL
Intervention: Deep breathing (Kussmaul's respiration)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Respiratory distress
Number of subjects: 350
Study: 1599984

Group type: EXPERIMENTAL
Intervention: Amitriptyline combined with a low dose of flupentixol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3902326

Group type: EXPERIMENTAL
Intervention: Iodine concentration higher than 370 mgI/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodine concentration 370 mgI/ml or lower
Number of subjects: 0
Study: 30813966

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day
Number of subjects: 2816

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2816
Study: 28976895

Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA) continued
Number of subjects: 130

Group type: COMPARATOR
Intervention: 100 mg acetylsalicylic acid (ASA) stopped 72 hours before extraction
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel continued
Number of subjects: 130

Group type: COMPARATOR
Intervention: 75 mg clopidogrel stopped 72 hours before extraction
Number of subjects: 130
Study: 27390285

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25091614

Group type: COMPARATOR
Intervention: Apical stimulation (Group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Septal stimulation (Group B)
Number of subjects: 19
Study: 21735072

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Risperidone vs Olanzapine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 174
Study: 19535419

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding (EBF) for 4-6 months
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Exclusive breast-feeding (EBF) for <4 months
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Duration of EBF (both groups)
Number of subjects: 1032
Study: 17768466

Group type: EXPERIMENTAL
Intervention: Under-sized trephine (0.25 mm disparity)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Over-sized trephine (0.50 mm disparity)
Number of subjects: 40
Study: 15871196

Group type: EXPERIMENTAL
Intervention: 0.375% hyperbaric bupivacaine solutions
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.375% isobaric bupivacaine solutions
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.375% hypobaric bupivacaine solutions
Number of subjects: 60
Study: 12411141

Group type: EXPERIMENTAL
Intervention: Lung protective group (n = 34) perfused with hypothermic protective solution to the pulmonary artery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lung protective group (n = 34)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 64
Study: 9558544

Group type: EXPERIMENTAL
Intervention: ART restorations using Fuji II glass ionomer cement (GIC)
Number of subjects: 53
Study: 7656906

Group type: EXPERIMENTAL
Intervention: MPA plus epirubicin
Number of subjects: 149

Group type: COMPARATOR
Intervention: Estramustine phosphate
Number of subjects: 149
Study: 2197860

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nifedipine and Ritodrine
Number of subjects: 66
Study: 363108

Group type: EXPERIMENTAL
Intervention: Group A (donor transplant 0.5 mm larger than recipient bed)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Group B (donor buttons equal in size to recipient bed)
Number of subjects: 92
Study: 31252284

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NME) for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 28336740

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Without intra-arterial treatment (IAT)
Number of subjects: 0
Study: 25337976

Group type: COMPARATOR
Intervention: Control scenario (white male)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Experimental scenario (black male)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Experimental scenario (white female)
Number of subjects: 113
Study: 24488919

Group type: EXPERIMENTAL
Intervention: Myo-inositol, D-chiro-inositol, folic acid and manganese (MDFM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22960584

Group type: EXPERIMENTAL
Intervention: Semidemand method for nipple feeding
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 86
Study: 19453310

Group type: EXPERIMENTAL
Intervention: Dopexamine treatment
Number of subjects: 935
Study: 17323070

Group type: COMPARATOR
Intervention: Cycling at a constant power output of 75 W (P1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cycling with power output alternating between 50 and 100 W every 5 min (P2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cycling with power output alternating in reverse order (P3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cycling with power output alternating between 25 and 125 W (P4)
Number of subjects: 48
Study: 14699486

Group type: EXPERIMENTAL
Intervention: Glucagon (bolus of 4.8 microg/kg plus infusion of 9.6 microg x kg(‐1) x h(‐1)) at high intragastric volume (75% of threshold volume for discomfort)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) at high intragastric volume
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) at low intragastric volume (perception threshold)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low intragastric volume
Number of subjects: 21
Study: 12439364

Group type: EXPERIMENTAL
Intervention: Fenoldopam (a selective dopamine receptor agonist) used as an adjunct during PCI for prevention of radiocontrast nephropathy (RCN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoldopam in diabetics with moderate renal failure
Number of subjects: 0
Study: 9676896

Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking after deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking during the session
Number of subjects: 0
Study: 8007592

Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy with physiological infusion of vasopressin
Number of subjects: 0
Study: 2707322

Group type: EXPERIMENTAL
Intervention: Listening condition (counting targets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading condition (ignoring stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichotic listening with speech masker
Number of subjects: 0
Study: 373073

Group type: EXPERIMENTAL
Intervention: 50 mg trimipramine
Number of subjects: 9

Group type: COMPARATOR
Intervention: 25 mg trimipramine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31805614

Group type: EXPERIMENTAL
Intervention: Brief mindfulness training program (four sessions)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 103
Study: 31099085

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 + 2000 mg calcium/d (n = 73)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (n = 76)
Number of subjects: 149
Study: 28973065

Group type: EXPERIMENTAL
Intervention: Systematic ICU admission program (n=1519 participants)
Number of subjects: 3037

Group type: COMPARATOR
Intervention: Standard practice (n=1518 participants)
Number of subjects: 3037
Study: 25637380

Group type: COMPARATOR
Intervention: Standard treatment (arm A): FEC100 (500, 100, and 500 mg/m(2) for 3 cycles) followed by docetaxel (100 mg/m(2) for 3 cycles)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Adapted treatment (arm B): 2 cycles of FEC100, switch to docetaxel if tumor size decreased by <30% after 2 cycles or <50% after 4 cycles; otherwise, FEC100 for six cycles before surgery
Number of subjects: 264
Study: 23382321

Group type: EXPERIMENTAL
Intervention: Water ingestion with LBNP
Number of subjects: 12

Group type: COMPARATOR
Intervention: LBNP
Number of subjects: 12
Study: 21392667

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) followed by transpalatal arch (TPA) therapy and extraction of deciduous canines
Number of subjects: 70

Group type: COMPARATOR
Intervention: No orthodontic treatment (control group)
Number of subjects: 70
Study: 19443338

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Completion of RT treatment
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Completion of induction or consolidation plus concomitant treatment
Number of subjects: 139
Study: 18633754

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/day for three months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study: 14985686

Group type: EXPERIMENTAL
Intervention: New prediction equation for REE
Number of subjects: 239

Group type: COMPARATOR
Intervention: Existing formulae for predicting REE
Number of subjects: 239